
Genmab A/S: shareholders and insiders
Price
$50.60
November 20, 2026Market cap $32.5B
What Ploutos Investor adds for Genmab A/S
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2017
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Sorry, we do not have enough data
for purchases and sales by Genmab A/S's insiders
Why?
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Darwin Global Management, Ltd.with 2 more personsShare of class5.90%
- BlackRock, Inc.Share of class5.60%
- Orbis Investment Managementwith 1 more personShare of class5.30%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Darwin Global Management, Ltd.with 2 more persons | 5.90% | 3.67M | Oct 5, 2026 | 13G | |
| BlackRock, Inc. | 5.60% | 3.71M | Apr 23, 2025 | 13G/A | |
| Orbis Investment Managementwith 1 more person | 5.30% | 3.32M | Aug 14, 20264 filings since Nov 14, 2025 | 13G/A |
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter×26.1
- Renaissance TechnologiesIn the quarter-35%
- Citadel Advisors (Griffin)In the quarter-30%
- Millennium Mgmt (Englander)In the quarter-17%
- AQR CapitalIn the quarter+26%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 3.54M | ×26.1 | $126M | 0.20% |
| Renaissance Technologies | 2.27M | -35% | $81M | 0.11% |
| Citadel Advisors (Griffin) | 1.73M | -30% | $62M | 0.03% |
| Millennium Mgmt (Englander) | 756.5K | -17% | $27M | 0.02% |
| AQR Capital | 133.6K | +26% | $4.8M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short sales in daily trading
How much of the shares that changed hands were short sales, in the off-exchange trades brokers report each day.
In the last 14 sessions, 40.6% of the shares in the reported trades were short sales, against 54.2% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 40.6%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 54.2%
- Change
- -13.6 pts
- Short sales a dayon average, of 1.66M shares
- 675.4K
- More than atof 3,666 US-listed companies, same days
- 21%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 66.6%
- Oct 15, 2026: Short sales 64.4%
- Oct 16, 2026: Short sales 43.6%
- Oct 19, 2026: Short sales 47.2%
- Oct 20, 2026: Short sales 71.4%
- Oct 21, 2026: Short sales 44.2%
- Oct 22, 2026: Short sales 66.2%
- Oct 23, 2026: Short sales 59.5%
- Oct 26, 2026: Short sales 64.5%
- Oct 27, 2026: Short sales 58.2%
- Oct 28, 2026: Short sales 61%
- Oct 29, 2026: Short sales 31.4%
- Oct 30, 2026: Short sales 28.9%
- Nov 2, 2026: Short sales 44.9%
- Nov 3, 2026: Short sales 38.1%
- Nov 4, 2026: Short sales 42%
- Nov 5, 2026: Short sales 33.9%
- Nov 6, 2026: Short sales 17.6%
- Nov 9, 2026: Short sales 48.7%
- Nov 10, 2026: Short sales 50.6%
- Nov 11, 2026: Short sales 55.5%
- Nov 12, 2026: Short sales 56.3%
- Nov 13, 2026: Short sales 47.7%
- Nov 16, 2026: Short sales 46.3%
- Nov 17, 2026: Short sales 65.9%
- Nov 18, 2026: Short sales 41.5%
- Nov 19, 2026: Short sales 41%
- Nov 20, 2026: Short sales 31.4%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half. Shares held short, which are published twice a month, are not included here.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IBBiShares Biotechnology ETFWeight in the fund1.12%
- IXJiShares Global Healthcare ETFWeight in the fund0.22%
- DFIVDimensional International Value ETFWeight in the fund0.17%
- EFGiShares MSCI EAFE Growth ETFWeight in the fund0.16%
- IEURiShares Core MSCI Europe ETFWeight in the fund0.11%
- VGKVanguard European Stock Index FundWeight in the fund0.11%
- AVDEAvantis International Equity ETFWeight in the fund0.10%
- DBEFXtrackers MSCI EAFE Hedged Equity ETFWeight in the fund0.09%
- EFAViShares MSCI EAFE Min Vol Factor ETFWeight in the fund0.08%
- EFAiShares MSCI EAFE ETFWeight in the fund0.08%
28 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 253
- Q4 2025: Managers 294
- Q1 2026: Managers 276
- Q2 2026: Managers 290
Institutional investors by quarter
The fund managers holding GMAB, quarter by quarter, from Q1 2014 to Q2 2025, 40 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 290 managers held 102M shares, worth $2.8B. During the quarter 50 opened a position, 36 closed one, 101 added and 98 trimmed.
The largest holders, Q2 2026
- Paradigm Biocapital AdvisorsIn the quarter+65%
- Orbis Allan GrayIn the quarter-12%
- AlliancebernsteinIn the quarter-9.5%
- Deerfield ManagementIn the quarter+179%
- Deep Track CapitalIn the quarter+54%
- Arrowstreet Capital, Limited PartnershipIn the quarter
- BlackRockIn the quarter+3.0%
- Sofinnova InvestmentsIn the quarter+438%
- Renaissance TechnologiesIn the quarter-20%
- Two Sigma InvestmentsIn the quarter+50%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Paradigm Biocapital Advisors | 13.13M | +65% | $361M |
| Orbis Allan Gray | 11.37M | -12% | $312M |
| Alliancebernstein | 8.64M | -9.5% | $232M |
| Deerfield Management | 6.87M | +179% | $189M |
| Deep Track Capital | 5.65M | +54% | $155M |
| Arrowstreet Capital, Limited Partnership | 4.98M | $137M | |
| BlackRock | 4.67M | +3.0% | $128M |
| Sofinnova Investments | 4.05M | +438% | $111M |
| Renaissance Technologies | 3.52M | -20% | $97M |
| Two Sigma Investments | 3.51M | +50% | $96M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Genmab A/S's filings show?
Who buys and sells is one part of Genmab A/S's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have GMAB's insiders bought or sold?
From – to – Genmab A/S's insiders reported no purchase or sale of shares on the market.
Which well-known managers hold GMAB?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Point72 (Cohen)'s, worth $126M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.